Nursing Elites

1. A healthcare provider is reviewing the health care record of a client who is asking about conjugated equine estrogens. The healthcare provider should inform the client this medication is contraindicated in which of the following conditions?

• A. Atrophic vaginitis
• B. Dysfunctional uterine bleeding
• C. Osteoporosis
• D. Thrombophlebitis

Correct answer: D

Rationale: Conjugated equine estrogens are contraindicated in individuals with a history of thrombophlebitis due to the increased risk of thrombotic events associated with estrogen use. Thrombophlebitis is a condition characterized by inflammation and blood clot formation in the veins, and estrogen therapy can exacerbate this condition, leading to serious complications such as deep vein thrombosis. Therefore, caution is advised when considering estrogen therapy in clients with a history of thrombophlebitis to prevent adverse outcomes. Choices A, B, and C are not contraindications for conjugated equine estrogens. Atrophic vaginitis and dysfunctional uterine bleeding may actually be conditions for which estrogen therapy is indicated. Osteoporosis can also be managed with estrogen therapy in certain cases to help prevent bone density loss.

2. When administering an Antiulcer Agent, you should be more cautious when administering it to:

• A. A healthy 27-year-old patient
• B. Patient with renal failure
• C. Elderly patients
• D. Choices B & C

Correct answer: D

Rationale: When administering an antiulcer agent, caution is warranted in patients with renal failure due to the potential impact on drug metabolism and excretion. Additionally, elderly patients may be more susceptible to adverse effects from antiulcer agents due to age-related physiological changes. Therefore, it is important to be more cautious when administering antiulcer agents to patients with renal failure and elderly patients. Choice A, a healthy 27-year-old patient, would typically not require as much caution compared to patients with renal failure or elderly patients when administering antiulcer agents. Therefore, choices B & C are the correct options for increased caution.

3. When teaching parents of a school-age child about transdermal Methylphenidate, which instruction should the nurse include?

• A. Apply one patch once per day.
• B. Leave the patch on for 9 hours.
• C. Apply the patch to the child's waistline.
• D. Use the opened tray within 6 months.

Correct answer: B

Rationale: When administering transdermal Methylphenidate, the patch should be left on for 9 hours per day to ensure optimal absorption and effectiveness of the medication. This duration helps maintain a consistent level of the drug in the child's system. Incorrect options: A) Applying one patch once per day is not the correct dosing regimen for transdermal Methylphenidate. C) The patch should not be applied to the child's waistline as it is recommended to apply it to a clean, dry area. D) Using the opened tray within 6 months is not directly related to the administration of transdermal Methylphenidate.

4. A client with chronic renal disease is receiving therapy with epoetin alfa. Which of the following laboratory results should the nurse review for an indication of a therapeutic effect of the medication?

• A. The leukocyte count
• B. The platelet count
• C. The hematocrit (Hct)
• D. The erythrocyte sedimentation rate (ESR)

Correct answer: C

Rationale: The correct answer is C: The hematocrit (Hct). Monitoring the hematocrit is essential to assess the therapeutic effect of epoetin alfa because this medication stimulates red blood cell production in clients with chronic renal disease. The leukocyte count (choice A) and platelet count (choice B) are not directly affected by epoetin alfa therapy. The erythrocyte sedimentation rate (ESR) (choice D) is a non-specific marker of inflammation and is not used to monitor the therapeutic effect of epoetin alfa.

5. When starting Alfuzosin for the treatment of Benign Prostatic Hyperplasia, a nurse is providing teaching to a client. The nurse should instruct the client that which of the following is an adverse effect of this medication?

• A. Bradycardia
• B. Edema
• C. Hypotension
• D. Tremor

Correct answer: C

Rationale: The correct adverse effect of Alfuzosin is hypotension. Alfuzosin relaxes muscle tone in veins, leading to decreased cardiac output and subsequent hypotension. Patients on this medication should be advised to change positions slowly to prevent a sudden drop in blood pressure. Choice A, Bradycardia, is not a common adverse effect of Alfuzosin. Choice B, Edema, is not typically associated with Alfuzosin use. Choice D, Tremor, is also not a common adverse effect of Alfuzosin.

Similar Questions